Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer

Participants receive EC chemotherapy combined with Adebrelimab for 2 cycles, and the efficacy will be evaluated. If the efficacy evaluation is SD/PR/CR, concurrent chemoradiotherapy combined with EC(2 cycles) + Adebrelimab will be initiated. After concurrent chemoradiotherapy + Adebrelimab, Adebrelimab was maintained until PD or intolerance or for at most 2 years.

Inclusion criteria

• Aged 18-75 years;
• Histologically confirmed ES-SCLC (per the Veterans Administration Lung Study Group [VALG] staging system) ;
• Must sign a written informed consent form prior to any study specific procedures;
• No prior treatment for ES-SCLC;
• No more than 5 lesions (including metastases),and at least one measurable lesion that meets RECIST 1.1 evaluation criteria;
• Life expectancy more than 3 months;
• ECOG PS 0-1

Exclusion criteria

• Previous treatment with radiochemotherapy for limited-stage small cell lung cancer;
• Subjects who previously received systemic antitumor or Immune checkpoint inhibitor therapy ;
• Active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs); replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment;
• Active brain metastases, Leptomeningeal metastasis(untreated central nervous system (CNS) metastases unless asymptomatic and lesion size<1cm;
• Patients with spinal cord compression;
• Patients with multiple liver metastases(except isolated lesion and lesion size<2cm);
• Uncontrollable third cavity effusion (e.g. a large amount of pleural effusion, ascites, or pericardial effusion, etc.) requiring repeated drainage, which was judged by the investigator to be unsuitable for study;
• The investigator judges that there are any patients who endanger the patient's safety, interfere with the study assessment, and have poor compliance.